{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-051845","form_type":"8-K","ticker":"MED","cik":"0000910329","company_name":"MEDIFAST INC","filed_at":"2026-08-03T20:12:19+00:00","discovered_at":"2026-08-03T20:13:00.347762+00:00","generated_at":"2026-08-03T20:13:08.439841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medifast Q2 2026 revenue $76.4M (-27.6% YoY), net loss $3.1M; guides Q3 rev $60-80M","bullets":["Revenue $76.4M, down 27.6% YoY; net loss $3.1M ($0.28 loss per share) vs net income $2.5M ($0.22 EPS) in Q2 2025.","Active earning coaches 11,700, down 48.7% YoY; revenue per active earning coach $6,529, up 41% YoY.","Gross profit margin 69.9% vs 72.6% YoY; SG&A as % of revenue 75.6% vs 73.6%.","Cash and investments $169.8M, no debt; working capital $160.5M.","Q3 2026 revenue guidance $60-80M, loss per share $0.15-0.65; full year 2026 revenue $270-300M, loss per share $0.25-1.75."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-051845","json":"https://secwatch.observer/filing/0001628280-26-051845.json","markdown":"https://secwatch.observer/filing/0001628280-26-051845.md","text":"https://secwatch.observer/filing/0001628280-26-051845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910329/000162828026051845/0001628280-26-051845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910329/000162828026051845/med-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:13:08.439841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}